,279,312 Immunomodulation seems to be a key mechanism of the pleiotropic cardioprotective effects of GLP-1- and SGLT2-based drugs, also supported by the promising results of the large clinical trials on monoclonal antibodies against IL-1β in patients with T2DM.349. Here, GLP1R is linked to type 2 diabetes mellitus.